Search Results - "Yagoda, A V"

Portal Vein Thrombosis in Liver Cirrhosis. Part 2: Treatment, Primary and Secondary Prevention by Yagoda, A. V., Koroy, P. V., Baisaeva, L. S., Dudov, T. R.

“…In most cases, portal vein thrombosis progresses without treatment; spontaneous recanalization of portal vein develops in 42 % of patients with liver…”
Get full text

Castleman’s Disease. Association with System Scleroderma by Yagoda, A. V., Koroy, P. V., Kharchenko, D. P., Bondarenko, E. V.

“…   The article presents an observation of a rare benign lymphoproliferative disease — Castleman’s disease, with pronounced systemic symptoms. The clinical case…”
Get full text

Paraneoplastic Vasculitis in a Patient with Astrocytoma of the Brain by Yagoda, A. V., Rybas, A. V., Danilova, E. N., Gromova, Yu. V.

“…Clinical case of paraneoplastic vasculitis аssociated a brain tumor was presented. Paraneoplastic vasculitis is a rare type of paraneoplastic syndrome. The…”
Get full text

DIAGNOSTIC SIGNIFICANCE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN PATIENTS WITH PRIMARY MITRAL VALVE PROLAPSE by Yagoda, A. V., Gladkikh, N. N., Zangelova, Т. E.

“…Aim. To evaluate diagnostic significance of the type A vascular endothelial growth factor (VEGF-A) and its receptors type 1 and 2 (VEGF-R1 and VEGF-R2) in…”
Get full text

The specifics of adhesion function of endothelium in various clinical variants of primary mitral valve prolapse by Yagoda, A. V., Gladkikh, N. N., Gladkikh, L. N.

“…Aim. To assess the condition of adhesion function of endothelium in various clinical variants of primary mitral valve prolapse (MVP). Material and methods…”
Get full text

AUTOIMMUNE ASPECTS OF COLLAGEN HOMEOSTASIS DISORDER IN UNDIFFERENTIATED CONNECTIVE TISSUE DYSPLASIA by Yagoda, A. V., Gladkikh, N. N.

“…The levels of autoantibodies to collagen type I, II, III, IV and V were studied in blood plasma of 130 patients (18-32 years old) with undifferentiated…”
Get full text

Risk of Stroke After Exacerbation of Ischemic Heart Disease: Data of 3‑Years Follow-up by Brazhnik, V A, Minushkina, L O, Evdokimova, M A, Galyavich, A S, Tereshchenko, S N, Koziolova, N A, Glezer, M G, Yagoda, A V, Khorolets, E V, Dankovtseva, E N, Boeva, O I, Konstantinov, V O, Zateishchikov, D A

“…to analyze possible associations of clinical and genetic factors with development of ischemic stroke after exacerbation of ischemic heart disease (IHD). The…”
Get more information

Experience of therapy of chronic viral hepatitis c patients with unfavourable response predictors by N. I. Geyvandova, A. V. Lipov, P. V. Koroy, A. V. Yagoda, S. S. Rogova

“…Introduction in practice of therapeutic establishments in the RF of antiviral therapy of chronic viral hepatitis in the form of interferon-free schemes led to…”
Get full text

Mediators of intracellular interactions and endothelial function in myxomatous mitral valve prolapse by Yagoda, A. V., Gladkikh, N. N., Gladkikh, L. N., Novikova, M. V., Saneeva, G. A.

“…Aim. To study the selected mediators of intracellular interactions and endothelial function in patients with myxomatous mitral valve prolapse (MVP). Material…”
Get full text

Thromboxane-prostacyclin balance and platelet aggregability in patients with minor cardiac abnormalities by Iagoda, A V, Gladkikh, N N

“…To reveal changes in the thromboxane-prostacyclin balance and platelet aggregability in patients with various variants of minor cardiac abnormalities. Six-five…”
Get full text

Regulators of fibrinolysis in chronic viral pathology of the liver by Iagoda, A V, Koroĭ, P V

“…To investigate a clinicopathogenetic role of fibrinolysis regulators in chronic viral hepatitis (CVH) and viral cyrrhosis of the liver (CL). Seventy patients…”
Get full text

Endothelial vasoactive mediators in young patients with minor heart anomalies by A. V. Yagoda, N. N. Gladkikh

“…Aim. To investigate regulatory vasoactive mediators – endothelin-1 (ET-1), 6-ketoprostaglandin F1α (6-keto-PGF1α), thromboxane В2 (TXВ2) – in young patients…”
Get full text

Constitutional and genetic model of high coronary heart disease risk by O. I. Boeva, A. V. Yagoda, E. A. Koshcheeva

“…Aim. To study the complex somato-typological and psycho-typological features of coronary heart disease (CHD) patients, to assess prognostic value of these…”
Get full text

Synthesis of eicosanoids by circulating mononuclears in healthy people and in patients with liver cirrhosis by Mosin, V I, Yagoda, A V

“…The synthesis of some of the products of cycloxygenase and lipoxygenase metabolism of arachidonic acid (AA) in mononuclear cells (MNCs) in vitro was studied…”
Get more information

Portal Vein Thrombosis in Liver Cirrhosis. Part 1: Epidemiology, Pathogenesis, Clinic, Diag-nosis, Impact on Prognosis by A. V. Yagoda, P. V. Koroy, L. S. Baisaeva, T. R. Dudov

“…Portal vein thrombosis is the most common thrombotic complication in patients with liver cirrhosis, especially in cases of severe forms. The pathogenesis is…”
Get full text

Effects of interferonotherapy on functional activity of platelets in chronic viral hepatitis and cirrhosis of the liver by Iagoda, A V, Koroĭ, P V

“…To characterize effects of interferon alpha (If-a) on functional activity of platelets in patients with chronic viral hepatitis (CVH) and viral hepatic…”
Get more information

Mediators of intercellular interactions and histological signs of chronic viral liver disease by P. V. Koroy, A. V. Yagoda, G. I. Gilyazova, I. S. Mukhoramova

“…Aim of investigation. To establish interrelation of intercellular interaction mediators with histological changes at chronic viral liver disease.Material and…”
Get full text

Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial) by Mayevskaya, M.V., Ivashkin, V.T., Bessonova, Ye.N., Bogomolov, P.O., Geyvandova, N.I., Zhdanov, K.V., Morozov, V.G., Pasechnikov, V.D., Khomenko, I.Yu, Yagoda, A.V.

“…Aim of investigation. Nowadays the question, whether pegylated interferon should be completely abandoned in the treatment of chronic hepatitis C (CHC) is still…”
Get full text

Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study by V. T. Ivashkin, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, M. V. Mayevskaya, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda

“…Aim of investigation. Comparative assessment of efficacy and safety of Pegaltevir and PegIntron in within pattern of combined antiviral therapy in previously…”
Get full text

ASSOCIATION OF TNF AND LTA GENES WITH ATHEROSCLEROSIS COMPLICATIONSIN PATIENTS WITH HISTORY OF ACUTE CORONARY SYNDROME by Zateyshchikov, D A, Pushkov, A A, Nikitin, A G, Brovkin, A N, Evdokimova, M A, Baklanova, T N, Tereschenko, S N, Dzhaiani, N A, Akatova, E V, Glezer, M G, Galyavich, A S, Koziolova, N A, Yagoda, A V, Boyeva, O I, Horolets, E V, Shlyk, S V, Volkova, E G, Konstantinov, V O, Nosikov, V V, Blagodatskih, K A

“…The aim of this study was to investigate an association of polymorphic markers G(-308)A of TNF gene and Thr26Asn of LTA gene with the frequency of poor…”
Get full text